Skip to main content

ISPBM: MODELADO ESTRUCTURAL DE LA INTERACCION ENTRE FACTORES DE TRANSCRIPCION Y DNA CON APLICACIONES BIOMEDICAS EN REDES Y MEDICINA DE SISTEMAS

BIO2017-85329-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSITAT POMPEU FABRA CCT

Resultados relacionados

Resultados totales (Incluyendo duplicados): 24
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Mining drug-target and drug-adverse drug reaction databases to identify target-adverse drug reaction relationships

  • Galletti, Cristiano
  • Mirela Bota, Patricia
  • Oliva Miguel, Baldomero
  • Fernández Fuentes, Narcís
The level of attrition on drug discovery, particularly at advanced stages, is very high due to unexpected adverse drug reactions (ADRs) caused by drug candidates, and thus, being able to predict undesirable responses when modulating certain protein targets would contribute to the development of safer drugs and have important economic implications. On the one hand, there are a number of databases that compile information of drug-target interactions. On the other hand, there are a number of public resources that compile information on drugs and ADR. It is therefore possible to link target and ADRs using drug entities as connecting elements. Here, we present T-ARDIS (Target-Adverse Reaction Database Integrated Search) database, a resource that provides comprehensive information on proteins and associated ADRs. By combining the information from drug-protein and drug-ADR databases, we statistically identify significant associations between proteins and ADRs. Besides describing the relationship between proteins and ADRs, T-ARDIS provides detailed description about proteins along with the drug and adverse reaction information. Currently T-ARDIS contains over 3000 ADR and 248 targets for a total of more 17 000 pairwise interactions. Each entry can be retrieved through multiple search terms including target Uniprot ID, gene name, adverse effect and drug name. Ultimately, the T-ARDIS database has been created in response to the increasing interest in identifying early in the drug development pipeline potentially problematic protein targets whose modulation could result in ADRs. Database URL: http://www.bioinsilico.org/T-ARDIS., Authors acknowledge support from MINECO grant numbers RYC2015-17519 and BIO2017-85329-R.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan

  • Jorba Argemí, Guillem
  • Aguirre Plans, Joaquim, 1993-
  • Junet, Valentin
  • Segú-Vergés, Cristina
  • Ruiz, José Luis
  • Pujol, Albert
  • Fernández Fuentes, Narcís
  • Mas, José Manuel
  • Oliva Miguel, Baldomero
Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of different responses depending on the patient. Exploring this collection of mechanisms is one of the clues for a future personalized medicine. The Therapeutic Performance Mapping System (TPMS) is a Systems Biology approach that generates multiple models of the mechanism of action of a drug. Each molecular mechanism generated could be associated to particular individuals, here defined as prototype-patients, hence the generation of models using TPMS technology may be used for detecting adverse effects to specific patients. TPMS operates by (1) modelling the responses in humans with an accurate description of a protein network and (2) applying a Multilayer Perceptron-like and sampling strategy to find all plausible solutions. In the present study, TPMS is applied to explore the diversity of mechanisms of action of the drug combination sacubitril/valsartan. We use TPMS to generate a wide range of models explaining the relationship between sacubitril/valsartan and heart failure (the indication), as well as evaluating their association with macular degeneration (a potential adverse effect). Among the models generated, we identify a set of mechanisms of action associated to a better response in terms of heart failure treatment, which could also be associated to macular degeneration development. Finally, a set of 30 potential biomarkers are proposed to identify mechanisms (or prototype-patients) more prone of suffering macular degeneration when presenting good heart failure response. All prototype-patients models generated are completely theoretical and therefore they do not necessarily involve clinical effects in real patients. Data and accession to software are available at http://sbi.upf.edu/data/tpms/., Public funders provided support for authors salaries: JAP, NFF and BO received support from the Spanish Ministry of Economy (MINECO) [BIO2017-85329-R] [RYC-2015-17519]; “Unidad de Excelencia María de Maeztu”, funded by the Spanish Ministry of Economy [ref: MDM-2014-0370]. The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I+D+i 2013-2016, funded by ISCIII and FEDER. GJ has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765912. VJ is part of a project (COSMIC; www.cosmic-h2020.eu) that has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765158. Funding for publication is from Agència de Gestió D'ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

On the use of direct-coupling analysis with a reduced alphabet of amino acids combined with super-secondary structure motifs for protein fold prediction

  • Anton, Bernat
  • Besalú, Mireia
  • Fornés Crespo, Oriol, 1983-
  • Bonet Martínez, Jaume, 1982-
  • Molina, Alexis
  • Molina Fernández, Rubén
  • Cuevas, Gemma de las
  • Fernández Fuentes, Narcís
  • Oliva Miguel, Baldomero
Direct-coupling analysis (DCA) for studying the coevolution of residues in proteins has been widely used to predict the three-dimensional structure of a protein from its sequence. We present RADI/raDIMod, a variation of the original DCA algorithm that groups chemically equivalent residues combined with super-secondary structure motifs to model protein structures. Interestingly, the simplification produced by grouping amino acids into only two groups (polar and non-polar) is still representative of the physicochemical nature that characterizes the protein structure and it is in line with the role of hydrophobic forces in protein-folding funneling. As a result of a compressed alphabet, the number of sequences required for the multiple sequence alignment is reduced. The number of long-range contacts predicted is limited; therefore, our approach requires the use of neighboring sequence-positions. We use the prediction of secondary structure and motifs of super-secondary structures to predict local contacts. We use RADI and raDIMod, a fragment-based protein structure modelling, achieving near native conformations when the number of super-secondary motifs covers >30-50% of the sequence. Interestingly, although different contacts are predicted with different alphabets, they produce similar structures., Spanish Ministry of Economy MINECO [BIO2014-57518-R, BIO2017-83591-R (FEDER, UE), BIO2017-85329-R (FEDER, UE)]; Generalitat de Catalunya [SGR17-1020].
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Human albumin impairs amyloid β-peptide fibrillation through its C-terminus: from docking modeling to protection against neurotoxicity in alzheimer's disease

  • Picón-Pagès, Pol
  • Bonet Martínez, Jaume, 1982-
  • García-García, Javier, 1982-
  • Garcia-Buendia, Joan
  • Gutierrez, Daniela
  • Valle, Javier
  • Gómez-Casuso, Carmen E.S.
  • Sidelkivska, Valeriya
  • Alvarez, Alejandra
  • Perálvarez Marín, Alex
  • Suades, Albert
  • Fernàndez Busquets, Xavier
  • Andreu Martínez, David
  • Vicente García, Rubén, 1978-
  • Oliva Miguel, Baldomero
  • Muñoz López, Francisco José, 1964-
Alzheimer's disease (AD) is a neurodegenerative process characterized by the accumulation of extracellular deposits of amyloid β-peptide (Aβ), which induces neuronal death. Monomeric Aβ is not toxic but tends to aggregate into β-sheets that are neurotoxic. Therefore to prevent or delay AD onset and progression one of the main therapeutic approaches would be to impair Aβ assembly into oligomers and fibrils and to promote disaggregation of the preformed aggregate. Albumin is the most abundant protein in the cerebrospinal fluid and it was reported to bind Aβ impeding its aggregation. In a previous work we identified a 35-residue sequence of clusterin, a well-known protein that binds Aβ, that is highly similar to the C-terminus (CTerm) of albumin. In this work, the docking experiments show that the average binding free energy of the CTerm-Aβ1-42 simulations was significantly lower than that of the clusterin-Aβ1-42 binding, highlighting the possibility that the CTerm retains albumin's binding properties. To validate this observation, we performed in vitro structural analysis of soluble and aggregated 1 μM Aβ1-42 incubated with 5 μM CTerm, equimolar to the albumin concentration in the CSF. Reversed-phase chromatography and electron microscopy analysis demonstrated a reduction of Aβ1-42 aggregates when the CTerm was present. Furthermore, we treated a human neuroblastoma cell line with soluble and aggregated Aβ1-42 incubated with CTerm obtaining a significant protection against Aβ-induced neurotoxicity. These in silico and in vitro data suggest that the albumin CTerm is able to impair Aβ aggregation and to promote disassemble of Aβ aggregates protecting neurons., This work was supported by the Spanish Ministry of Economy and Business through grant Plan Estatal SAF2017-83372-R & SAF2014-52228-R (FEDER funds/UE) to FJM and RV; BIO2017-85329-R to BO; AGL2014-52395-C2 and AGL2017- 84097-C2-2-R to D.A.; MDM-2014-0370 through the “María de Maeztu” Programme for Units of Excellence in R&D to “Departament de Ciències Experimentals i de la Salut”; the Chilean Government through Fondecyt 11611065 and AFB170005 to AA, and REDES 180084 to AA and FJM; ISGlobal and IBEC are members of the CERCA Programme, Generalitat de Catalunya.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm

  • Artigas, Laura
  • Coma Camprodón, Mireia
  • Matos Filipe, Pedro
  • Aguirre Plans, Joaquim, 1993-
  • Farrés, Judith
  • Valls, Raquel
  • Fernández Fuentes, Narcís
  • Haba-Rodríguez, Juan de la
  • Olvera, Alex
  • Barbera, Jose
  • Morales-Barrera, Rafael
  • Oliva Miguel, Baldomero
  • Mas, José Manuel
From January 2020, COVID-19 is spreading around the world producing serious respiratory symptoms in infected patients that in some cases can be complicated by the severe acute respiratory syndrome, sepsis and septic shock, multiorgan failure, including acute kidney injury and cardiac injury. Cost and time efficient approaches to reduce the burthen of the disease are needed. To find potential COVID-19 treatments among the whole arsenal of existing drugs, we combined system biology and artificial intelligence-based approaches. The drug combination of pirfenidone and melatonin has been identified as a candidate treatment that may contribute to reduce the virus infection. Starting from different drug targets the effect of the drugs converges on human proteins with a known role in SARS-CoV-2 infection cycle. Simultaneously, GUILDify v2.0 web server has been used as an alternative method to corroborate the effect of pirfenidone and melatonin against the infection of SARS-CoV-2. We have also predicted a potential therapeutic effect of the drug combination over the respiratory associated pathology, thus tackling at the same time two important issues in COVID-19. These evidences, together with the fact that from a medical point of view both drugs are considered safe and can be combined with the current standard of care treatments for COVID-19 makes this combination very attractive for treating patients at stage II, non-severe symptomatic patients with the presence of virus and those patients who are at risk of developing severe pulmonary complications., LA, MC, PMF, JF, RV and JMM have commercial affiliation to Anaxomics Biotech SL. The funders provided support in the form of salaries for authors JAP, NFF and PMF, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. JAP, NFF and BO acknowledge support from the Spanish Ministry of Economy (MINECO) [BIO2017-85329-R] [RYC-2015-17519]; Unidad de Excelencia María de Maeztu”, funded by the Spanish Ministry of Economy [ref: MDM-2014-0370].PMF has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765912.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Evaluation of computationally designed peptides against TWEAK, a cytokine of the tumour necrosis factor ligand family

  • Badia Villanueva, Miriam
  • Defaus, Sira
  • Foj, Ruben
  • Andreu Martínez, David
  • Oliva Miguel, Baldomero
  • Sierra, Angels
  • Fernández Fuentes, Narcís
The tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumour necrosis factor ligand family and has been shown to be overexpressed in tumoral cells together with the fibroblast growth factor-inducible 14 (Fn14) receptor. TWEAK-Fn14 interaction triggers a set of intracellular pathways responsible for tumour cell invasion and migration, as well as proliferation and angiogenesis. Hence, modulation of the TWEAK-Fn14 interaction is an important therapeutic goal. The targeting of protein-protein interactions by external agents, e.g., drugs, remains a substantial challenge. Given their intrinsic features, as well as recent advances that improve their pharmacological profiles, peptides have arisen as promising agents in this regard. Here, we report, by in silico structural design validated by cell-based and in vitro assays, the discovery of four peptides able to target TWEAK. Our results show that, when added to TWEAK-dependent cellular cultures, peptides cause a down-regulation of genes that are part of TWEAK-Fn14 signalling pathway. The direct, physical interaction between the peptides and TWEAK was further elucidated in an in vitro assay which confirmed that the bioactivity shown in cell-based assays was due to the targeting of TWEAK. The results presented here are framed within early pre-clinical drug development and therefore these peptide hits represent a starting point for the development of novel therapeutic agents. Our approach exemplifies the powerful combination of in silico and experimental efforts to quickly identify peptides with desirable traits., The authors received support from the Spanish Ministry of Science (MINECO) [RYC2015-17519, BIO2017-83591-R, BIO2014-57518R, BIO2017-85329-R, AGL2013-48923-C2 and AGL2017-89097-C2-R2], the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) [FIS-PI14/00336 and FIS-PI18/00916], the EU Action NADIR FP7-228394 and the Maria de Maeztu Program for Center of Excellence program (AEI CEX2018-000792-M.).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

SPServer: split-statistical potentials for the analysis of protein structures and protein-protein interactions

  • Aguirre Plans, Joaquim, 1993-
  • Meseguer, Alberto
  • Molina Fernández, Rubén
  • Marín López, Manuel Alejandro, 1987-
  • Jumde, Gaurav
  • Casanova, Kevin
  • Bonet Martínez, Jaume, 1982-
  • Fornés Crespo, Oriol, 1983-
  • Fernández Fuentes, Narcís
  • Oliva Miguel, Baldomero
Background: Statistical potentials, also named knowledge-based potentials, are scoring functions derived from empirical data that can be used to evaluate the quality of protein folds and protein-protein interaction (PPI) structures. In previous works we decomposed the statistical potentials in different terms, named Split-Statistical Potentials, accounting for the type of amino acid pairs, their hydrophobicity, solvent accessibility and type of secondary structure. These potentials have been successfully used to identify near-native structures in protein structure prediction, rank protein docking poses, and predict PPI binding affinities. Results: Here, we present the SPServer, a web server that applies the Split-Statistical Potentials to analyze protein folds and protein interfaces. SPServer provides global scores as well as residue/residue-pair profiles presented as score plots and maps. This level of detail allows users to: (1) identify potentially problematic regions on protein structures; (2) identify disrupting amino acid pairs in protein interfaces; and (3) compare and analyze the quality of tertiary and quaternary structural models. Conclusions: While there are many web servers that provide scoring functions to assess the quality of either protein folds or PPI structures, SPServer integrates both aspects in a unique easy-to-use web server. Moreover, the server permits to locally assess the quality of the structures and interfaces at a residue level and provides tools to compare the local assessment between structures. SERVER ADDRESS: https://sbi.upf.edu/spserver/., This work was supported by the Spanish Ministry of Science and Innovation (MICINN) [BIO2017-85329-R (co-funded by ERDF,UE)]. BO also acknowledges support from MICINN [ref: MDM-2014-0370]. NFF acknowledges support from [BIO2017-83591-R (co-funded by ERDF, UE)] and [RYC-2015-17519]. We also akcnowledge support from the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and Grants PT13/0001/0023 of the PEI +D+i 2013–2016, funded by ISCIII and co-funded by ERDF of EU. BO and NFF acknowledge Agència de Gestió d’Ajuts Universitaris I de Recerca de la Generalitat de Catalunya, grant SGR17-1020, and the Council for the Catalan Republic contribution to cover the expenses of publication.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

An ensemble learning approach for modeling the systems biology of drug-induced injury

  • Aguirre Plans, Joaquim, 1993-
  • Piñero González, Janet, 1977-
  • Souza, Terezinha
  • Callegaro, Giulia
  • Kunnen, Steven J.
  • Sanz, Ferran
  • Fernández Fuentes, Narcís
  • Furlong, Laura I., 1971-
  • Guney, Emre
  • Oliva Miguel, Baldomero
Background: Drug-induced liver injury (DILI) is an adverse reaction caused by the intake of drugs of common use that produces liver damage. The impact of DILI is estimated to affect around 20 in 100,000 inhabitants worldwide each year. Despite being one of the main causes of liver failure, the pathophysiology and mechanisms of DILI are poorly understood. In the present study, we developed an ensemble learning approach based on different features (CMap gene expression, chemical structures, drug targets) to predict drugs that might cause DILI and gain a better understanding of the mechanisms linked to the adverse reaction. Results: We searched for gene signatures in CMap gene expression data by using two approaches: phenotype-gene associations data from DisGeNET, and a non-parametric test comparing gene expression of DILI-Concern and No-DILI-Concern drugs (as per DILIrank definitions). The average accuracy of the classifiers in both approaches was 69%. We used chemical structures as features, obtaining an accuracy of 65%. The combination of both types of features produced an accuracy around 63%, but improved the independent hold-out test up to 67%. The use of drug-target associations as feature obtained the best accuracy (70%) in the independent hold-out test. Conclusions: When using CMap gene expression data, searching for a specific gene signature among the landmark genes improves the quality of the classifiers, but it is still limited by the intrinsic noise of the dataset. When using chemical structures as a feature, the structural diversity of the known DILI-causing drugs hampers the prediction, which is a similar problem as for the use of gene expression information. The combination of both features did not improve the quality of the classifiers but increased the robustness as shown on independent hold-out tests. The use of drug-target associations as feature improved the prediction, specially the specificity, and the results were comparable to previous research studies., The authors received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreements TransQST and eTRANSAFE (refs: 116030, 777365). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA companies in kind contribution. The authors also received support from Spanish Ministry of Economy (MINECO, refs: BIO2017–85329-R (FEDER, EU), RYC-2015-17519) as well as EU H2020 Programme 2014–2020 under grant agreement No. 676559 (Elixir-Excelerate) and from Agència de Gestió D’ajuts Universitaris i de Recerca Generalitat de Catalunya (AGAUR, ref.: 2017SGR01020). L.I.F. received support from ISCIII-FEDER (ref: CPII16/00026). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I + D + i 2013–2016, funded by ISCIII and FEDER. The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the MINECO (ref: MDM-2014-0370). J.A.P. received support from the CAMDA Travel Fellowship.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

On the prediction of DNA-binding preferences of C2H2-ZF domains using structural models: application on human CTCF

  • Meseguer, Alberto
  • Årman, Filip
  • Fornés Crespo, Oriol, 1983-
  • Molina Fernández, Rubén
  • Bonet Martínez, Jaume, 1982-
  • Fernández Fuentes, Narcís
  • Oliva Miguel, Baldomero
Cis2-His2 zinc finger (C2H2-ZF) proteins are the largest family of transcription factors in human and higher metazoans. To date, the DNA-binding preferences of many members of this family remain unknown. We have developed a computational method to predict their DNA-binding preferences. We have computed theoretical position weight matrices (PWMs) of proteins composed by C2H2-ZF domains, with the only requirement of an input structure. We have predicted more than two-third of a single zinc-finger domain binding site for about 70% variants of Zif268, a classical member of this family. We have successfully matched between 60 and 90% of the binding-site motif of examples of proteins composed by three C2H2-ZF domains in JASPAR, a standard database of PWMs. The tests are used as a proof of the capacity to scan a DNA fragment and find the potential binding sites of transcription-factors formed by C2H2-ZF domains. As an example, we have tested the approach to predict the DNA-binding preferences of the human chromatin binding factor CTCF. We offer a server to model the structure of a zinc-finger protein and predict its PWM., Spanish Ministry of Economy (MICINN) [BIO2017-85329-R, RYC2015-17519, MDM2014-0370] and European Regional Development Fund (FEDER) [BIO2017-85329-R, RYC-2015-17519, MDM-2014-0370]; Erasmus+ Fellowship 2019 by EU (to F.Å.); Research Formation of ‘Generalitat de Catalunya’ (FI) Fellowship (to A.M).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Differential regulation of insulin signalling by monomeric and oligomeric amyloid beta-peptide

  • Molina Fernández, Rubén
  • Picón-Pagès, Pol
  • Barranco Almohalla, Alejandro
  • Crepin, Giulia
  • Herrera-Fernández, Víctor
  • Garcia-Elias Heras, Anna
  • Fanlo-Ucar, Hugo
  • Fernàndez Busquets, Xavier
  • García Ojalvo, Jordi
  • Oliva Miguel, Baldomero
  • Muñoz López, Francisco José, 1964-
Alzheimer's disease and Type 2 diabetes are pathological processes associated to ageing. Moreover, there are evidences supporting a mechanistic link between Alzheimer's disease and insulin resistance (one of the first hallmarks of Type 2 diabetes). Regarding Alzheimer's disease, amyloid β-peptide aggregation into β-sheets is the main hallmark of Alzheimer's disease. At monomeric state, amyloid β-peptide is not toxic but its function in brain, if any, is unknown. Here we show, by in silico study, that monomeric amyloid β-peptide 1-40 shares the tertiary structure with insulin and is thereby able to bind and activate insulin receptor. We validated this prediction experimentally by treating human neuroblastoma cells with increasing concentrations of monomeric amyloid β-peptide 1-40. Our results confirm that monomeric amyloid β-peptide 1-40 activates insulin receptor autophosphorylation, triggering downstream enzyme phosphorylations and the glucose Transporter 4 translocation to the membrane. On the other hand, neuronal insulin resistance is known to be associated to Alzheimer's disease since early stages. We thus modelled the docking of oligomeric amyloid β-peptide 1-40 to insulin receptor. We found that oligomeric amyloid β-peptide 1-40 blocks insulin receptor, impairing its activation. It was confirmed in vitro by observing the lack of insulin receptor autophosphorylation, and also the impairment of insulin-induced intracellular enzyme activations and the glucose Transporter 4 translocation to the membrane. By biological system analysis, we have carried out a mathematical model recapitulating the process that turns amyloid β-peptide binding to insulin receptor from the physiological to the pathophysiological regime. Our results suggest that monomeric amyloid β-peptide 1-40 contributes to mimic insulin effects in the brain, which could be good when neurons have an extra requirement of energy beside the well-known protective effects on insulin intracellular signalling, while its accumulation and subsequent oligomerization blocks the insulin receptor producing insulin resistance and compromising neuronal metabolism and protective pathways., This work was supported by the Spanish Ministry of Science and Innovation and Agencia Estatal de Investigación plus European Regional Development Fund (FEDER Funds) through grants PID2020-117691RB-I00/AEI/10.13039/501100011033 (F.J.M.), SAF2017-83372-R (F.J.M.), BIO2017-85329-R (B.O.), PGC2018-101251-B-I00 (J.G.-O.) and RTI2018-094579-B-I00 (X.F.-B.). This work was also funded by the Spanish Institute of Health Carlos III by project reference AC20/00009 -FEDER/UE and European Research Era Net (ERANET) ERA-CVD_JTC2020-015 (J.G.-O.), by the ‘María de Maeztu Programme’ for Units of Excellence in Research and Development (R&D; award CEX2018-000792-M), Generalitat de Catalunya (Spain) through the grant 2017-SGR-908 (X.F.-B.) and Fundación QUAES through Cátedra QUAES-UPF de Biomedicina e Ingeniería Biomédica. The Instituto de Salud Global de Barcelona (ISGlobal) and Institute for Bioengineering of Catalonia (IBEC) are members of the Centres de Recerca de Catalunya (CERCA) Programme, Generalitat de Catalunya (Spain). We acknowledge support from the Spanish Ministry of Science, Innovation and Universities through the ‘Centro de Excelencia Severo Ochoa 2019–2023’ Programme (CEX2018-000806-S). This research is part of ISGlobal's Programme on the Molecular Mechanisms of Malaria, which is partially supported by the Fundación Ramón Areces. J.G.-O. also acknowledges support from the Institució Catalana de Recerca i Estudis Avançats (ICREA) Academia programme.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Sensing low intracellular potassium by NLRP3 results in a stable open structure that promotes inflammasome activation

  • Tapia-Abellán, Ana
  • Angosto-Bazarra, Diego
  • Alarcón-Vila, Cristina
  • Baños, María C.
  • Hafner-Bratkovič, Iva
  • Oliva Miguel, Baldomero
  • Pelegrín, Pablo
  • Pelegrín, Pablo
The NLRP3 inflammasome is activated by a wide range of stimuli and drives diverse inflammatory diseases. The decrease of intracellular K+ concentration is a minimal upstream signal to most of the NLRP3 activation models. Here, we found that cellular K+ efflux induces a stable structural change in the inactive NLRP3, promoting an open conformation as a step preceding activation. This conformational change is facilitated by the specific NLRP3 FISNA domain and a unique flexible linker sequence between the PYD and FISNA domains. This linker also facilitates the ensemble of NLRP3PYD into a seed structure for ASC oligomerization. The introduction of the NLRP3 PYD-linker-FISNA sequence into NLRP6 resulted in a chimeric receptor able to be activated by K+ efflux–specific NLRP3 activators and promoted an in vivo inflammatory response to uric acid crystals. Our results establish that the amino-terminal sequence between PYD and NACHT domain of NLRP3 is key for inflammasome activation., I.H.-B. would like to acknowledge the funding by the Slovenian Research Agency (project grant J3-1746 and core funding P4-0176), and B.O. would like to acknowledge the funding by the Ministerio de Economía, Industria y Competitividad and ERDF (BIO2017-85329-R). This work was supported by grants to A.T.-A. from the internal support program of the Medical Faculty, University of Tübingen, Fortüne-Antrag Nr. 2615-0-0 and to P.P. from FEDER/Ministerio de Ciencia, Innovación y Universidades—Agencia Estatal de Investigación (grant SAF2017-88276-R), Fundación Séneca (grants 20859/PI/18, 21081/PDC/19, and 0003/COVI/20), and the European Research Council (ERC-2013-CoG grant 614578 and ERC-2019-PoC grant 899636).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan

  • Jorba Argemí, Guillem
  • Aguirre Plans, Joaquim, 1993-
  • Junet, Valentin
  • Segú-Vergés, Cristina
  • Ruiz, José Luis
  • Pujol, Albert
  • Fernández Fuentes, Narcís
  • Mas, José Manuel
  • Oliva Miguel, Baldomero
Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of different responses depending on the patient. Exploring this collection of mechanisms is one of the clues for a future personalized medicine. The Therapeutic Performance Mapping System (TPMS) is a Systems Biology approach that generates multiple models of the mechanism of action of a drug. Each molecular mechanism generated could be associated to particular individuals, here defined as prototype-patients, hence the generation of models using TPMS technology may be used for detecting adverse effects to specific patients. TPMS operates by (1) modelling the responses in humans with an accurate description of a protein network and (2) applying a Multilayer Perceptron-like and sampling strategy to find all plausible solutions. In the present study, TPMS is applied to explore the diversity of mechanisms of action of the drug combination sacubitril/valsartan. We use TPMS to generate a wide range of models explaining the relationship between sacubitril/valsartan and heart failure (the indication), as well as evaluating their association with macular degeneration (a potential adverse effect). Among the models generated, we identify a set of mechanisms of action associated to a better response in terms of heart failure treatment, which could also be associated to macular degeneration development. Finally, a set of 30 potential biomarkers are proposed to identify mechanisms (or prototype-patients) more prone of suffering macular degeneration when presenting good heart failure response. All prototype-patients models generated are completely theoretical and therefore they do not necessarily involve clinical effects in real patients. Data and accession to software are available at http://sbi.upf.edu/data/tpms/., Public funders provided support for authors salaries: JAP, NFF and BO received support from the Spanish Ministry of Economy (MINECO) [BIO2017-85329-R] [RYC-2015-17519]; “Unidad de Excelencia María de Maeztu”, funded by the Spanish Ministry of Economy [ref: MDM-2014-0370]. The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I+D+i 2013-2016, funded by ISCIII and FEDER. GJ has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765912. VJ is part of a project (COSMIC; www.cosmic-h2020.eu) that has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765158. Funding for publication is from Agència de Gestió D'ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mining drug-target and drug-adverse drug reaction databases to identify target-adverse drug reaction relationships

  • Galletti, Cristiano
  • Mirela Bota, Patricia
  • Oliva Miguel, Baldomero
  • Fernández Fuentes, Narcís
The level of attrition on drug discovery, particularly at advanced stages, is very high due to unexpected adverse drug reactions (ADRs) caused by drug candidates, and thus, being able to predict undesirable responses when modulating certain protein targets would contribute to the development of safer drugs and have important economic implications. On the one hand, there are a number of databases that compile information of drug-target interactions. On the other hand, there are a number of public resources that compile information on drugs and ADR. It is therefore possible to link target and ADRs using drug entities as connecting elements. Here, we present T-ARDIS (Target-Adverse Reaction Database Integrated Search) database, a resource that provides comprehensive information on proteins and associated ADRs. By combining the information from drug-protein and drug-ADR databases, we statistically identify significant associations between proteins and ADRs. Besides describing the relationship between proteins and ADRs, T-ARDIS provides detailed description about proteins along with the drug and adverse reaction information. Currently T-ARDIS contains over 3000 ADR and 248 targets for a total of more 17 000 pairwise interactions. Each entry can be retrieved through multiple search terms including target Uniprot ID, gene name, adverse effect and drug name. Ultimately, the T-ARDIS database has been created in response to the increasing interest in identifying early in the drug development pipeline potentially problematic protein targets whose modulation could result in ADRs. Database URL: http://www.bioinsilico.org/T-ARDIS., Authors acknowledge support from MINECO grant numbers RYC2015-17519 and BIO2017-85329-R.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Evaluation of computationally designed peptides against TWEAK, a cytokine of the tumour necrosis factor ligand family

  • Badia Villanueva, Miriam
  • Defaus, Sira
  • Foj, Ruben
  • Andreu Martínez, David
  • Oliva Miguel, Baldomero
  • Sierra, Angels
  • Fernández Fuentes, Narcís
The tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumour necrosis factor ligand family and has been shown to be overexpressed in tumoral cells together with the fibroblast growth factor-inducible 14 (Fn14) receptor. TWEAK-Fn14 interaction triggers a set of intracellular pathways responsible for tumour cell invasion and migration, as well as proliferation and angiogenesis. Hence, modulation of the TWEAK-Fn14 interaction is an important therapeutic goal. The targeting of protein-protein interactions by external agents, e.g., drugs, remains a substantial challenge. Given their intrinsic features, as well as recent advances that improve their pharmacological profiles, peptides have arisen as promising agents in this regard. Here, we report, by in silico structural design validated by cell-based and in vitro assays, the discovery of four peptides able to target TWEAK. Our results show that, when added to TWEAK-dependent cellular cultures, peptides cause a down-regulation of genes that are part of TWEAK-Fn14 signalling pathway. The direct, physical interaction between the peptides and TWEAK was further elucidated in an in vitro assay which confirmed that the bioactivity shown in cell-based assays was due to the targeting of TWEAK. The results presented here are framed within early pre-clinical drug development and therefore these peptide hits represent a starting point for the development of novel therapeutic agents. Our approach exemplifies the powerful combination of in silico and experimental efforts to quickly identify peptides with desirable traits., The authors received support from the Spanish Ministry of Science (MINECO) [RYC2015-17519, BIO2017-83591-R, BIO2014-57518R, BIO2017-85329-R, AGL2013-48923-C2 and AGL2017-89097-C2-R2], the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) [FIS-PI14/00336 and FIS-PI18/00916], the EU Action NADIR FP7-228394 and the Maria de Maeztu Program for Center of Excellence program (AEI CEX2018-000792-M.).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm

  • Artigas, Laura
  • Coma Camprodón, Mireia
  • Matos Filipe, Pedro
  • Aguirre Plans, Joaquim, 1993-
  • Farrés, Judith
  • Valls, Raquel
  • Fernández Fuentes, Narcís
  • Haba-Rodríguez, Juan de la
  • Olvera, Alex
  • Barbera, Jose
  • Morales-Barrera, Rafael
  • Oliva Miguel, Baldomero
  • Mas, José Manuel
From January 2020, COVID-19 is spreading around the world producing serious respiratory symptoms in infected patients that in some cases can be complicated by the severe acute respiratory syndrome, sepsis and septic shock, multiorgan failure, including acute kidney injury and cardiac injury. Cost and time efficient approaches to reduce the burthen of the disease are needed. To find potential COVID-19 treatments among the whole arsenal of existing drugs, we combined system biology and artificial intelligence-based approaches. The drug combination of pirfenidone and melatonin has been identified as a candidate treatment that may contribute to reduce the virus infection. Starting from different drug targets the effect of the drugs converges on human proteins with a known role in SARS-CoV-2 infection cycle. Simultaneously, GUILDify v2.0 web server has been used as an alternative method to corroborate the effect of pirfenidone and melatonin against the infection of SARS-CoV-2. We have also predicted a potential therapeutic effect of the drug combination over the respiratory associated pathology, thus tackling at the same time two important issues in COVID-19. These evidences, together with the fact that from a medical point of view both drugs are considered safe and can be combined with the current standard of care treatments for COVID-19 makes this combination very attractive for treating patients at stage II, non-severe symptomatic patients with the presence of virus and those patients who are at risk of developing severe pulmonary complications., LA, MC, PMF, JF, RV and JMM have commercial affiliation to Anaxomics Biotech SL. The funders provided support in the form of salaries for authors JAP, NFF and PMF, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. JAP, NFF and BO acknowledge support from the Spanish Ministry of Economy (MINECO) [BIO2017-85329-R] [RYC-2015-17519]; Unidad de Excelencia María de Maeztu”, funded by the Spanish Ministry of Economy [ref: MDM-2014-0370].PMF has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765912.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Differential regulation of insulin signalling by monomeric and oligomeric amyloid beta-peptide

  • Molina Fernández, Rubén
  • Picón-Pagès, Pol
  • Barranco Almohalla, Alejandro
  • Crepin, Giulia
  • Herrera-Fernández, Víctor
  • Garcia-Elias Heras, Anna
  • Fanlo-Ucar, Hugo
  • Fernàndez Busquets, Xavier
  • García Ojalvo, Jordi
  • Oliva Miguel, Baldomero
  • Muñoz López, Francisco José, 1964-
Alzheimer's disease and Type 2 diabetes are pathological processes associated to ageing. Moreover, there are evidences supporting a mechanistic link between Alzheimer's disease and insulin resistance (one of the first hallmarks of Type 2 diabetes). Regarding Alzheimer's disease, amyloid β-peptide aggregation into β-sheets is the main hallmark of Alzheimer's disease. At monomeric state, amyloid β-peptide is not toxic but its function in brain, if any, is unknown. Here we show, by in silico study, that monomeric amyloid β-peptide 1-40 shares the tertiary structure with insulin and is thereby able to bind and activate insulin receptor. We validated this prediction experimentally by treating human neuroblastoma cells with increasing concentrations of monomeric amyloid β-peptide 1-40. Our results confirm that monomeric amyloid β-peptide 1-40 activates insulin receptor autophosphorylation, triggering downstream enzyme phosphorylations and the glucose Transporter 4 translocation to the membrane. On the other hand, neuronal insulin resistance is known to be associated to Alzheimer's disease since early stages. We thus modelled the docking of oligomeric amyloid β-peptide 1-40 to insulin receptor. We found that oligomeric amyloid β-peptide 1-40 blocks insulin receptor, impairing its activation. It was confirmed in vitro by observing the lack of insulin receptor autophosphorylation, and also the impairment of insulin-induced intracellular enzyme activations and the glucose Transporter 4 translocation to the membrane. By biological system analysis, we have carried out a mathematical model recapitulating the process that turns amyloid β-peptide binding to insulin receptor from the physiological to the pathophysiological regime. Our results suggest that monomeric amyloid β-peptide 1-40 contributes to mimic insulin effects in the brain, which could be good when neurons have an extra requirement of energy beside the well-known protective effects on insulin intracellular signalling, while its accumulation and subsequent oligomerization blocks the insulin receptor producing insulin resistance and compromising neuronal metabolism and protective pathways., This work was supported by the Spanish Ministry of Science and Innovation and Agencia Estatal de Investigación plus European Regional Development Fund (FEDER Funds) through grants PID2020-117691RB-I00/AEI/10.13039/501100011033 (F.J.M.), SAF2017-83372-R (F.J.M.), BIO2017-85329-R (B.O.), PGC2018-101251-B-I00 (J.G.-O.) and RTI2018-094579-B-I00 (X.F.-B.). This work was also funded by the Spanish Institute of Health Carlos III by project reference AC20/00009 -FEDER/UE and European Research Era Net (ERANET) ERA-CVD_JTC2020-015 (J.G.-O.), by the ‘María de Maeztu Programme’ for Units of Excellence in Research and Development (R&D; award CEX2018-000792-M), Generalitat de Catalunya (Spain) through the grant 2017-SGR-908 (X.F.-B.) and Fundación QUAES through Cátedra QUAES-UPF de Biomedicina e Ingeniería Biomédica. The Instituto de Salud Global de Barcelona (ISGlobal) and Institute for Bioengineering of Catalonia (IBEC) are members of the Centres de Recerca de Catalunya (CERCA) Programme, Generalitat de Catalunya (Spain). We acknowledge support from the Spanish Ministry of Science, Innovation and Universities through the ‘Centro de Excelencia Severo Ochoa 2019–2023’ Programme (CEX2018-000806-S). This research is part of ISGlobal's Programme on the Molecular Mechanisms of Malaria, which is partially supported by the Fundación Ramón Areces. J.G.-O. also acknowledges support from the Institució Catalana de Recerca i Estudis Avançats (ICREA) Academia programme.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

On the prediction of DNA-binding preferences of C2H2-ZF domains using structural models: application on human CTCF

  • Meseguer, Alberto
  • Årman, Filip
  • Fornés Crespo, Oriol, 1983-
  • Molina Fernández, Rubén
  • Bonet Martínez, Jaume, 1982-
  • Fernández Fuentes, Narcís
  • Oliva Miguel, Baldomero
Cis2-His2 zinc finger (C2H2-ZF) proteins are the largest family of transcription factors in human and higher metazoans. To date, the DNA-binding preferences of many members of this family remain unknown. We have developed a computational method to predict their DNA-binding preferences. We have computed theoretical position weight matrices (PWMs) of proteins composed by C2H2-ZF domains, with the only requirement of an input structure. We have predicted more than two-third of a single zinc-finger domain binding site for about 70% variants of Zif268, a classical member of this family. We have successfully matched between 60 and 90% of the binding-site motif of examples of proteins composed by three C2H2-ZF domains in JASPAR, a standard database of PWMs. The tests are used as a proof of the capacity to scan a DNA fragment and find the potential binding sites of transcription-factors formed by C2H2-ZF domains. As an example, we have tested the approach to predict the DNA-binding preferences of the human chromatin binding factor CTCF. We offer a server to model the structure of a zinc-finger protein and predict its PWM., Spanish Ministry of Economy (MICINN) [BIO2017-85329-R, RYC2015-17519, MDM2014-0370] and European Regional Development Fund (FEDER) [BIO2017-85329-R, RYC-2015-17519, MDM-2014-0370]; Erasmus+ Fellowship 2019 by EU (to F.Å.); Research Formation of ‘Generalitat de Catalunya’ (FI) Fellowship (to A.M).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Human albumin impairs amyloid β-peptide fibrillation through its C-terminus: from docking modeling to protection against neurotoxicity in alzheimer's disease

  • Picón-Pagès, Pol
  • Bonet Martínez, Jaume, 1982-
  • García-García, Javier, 1982-
  • Garcia-Buendia, Joan
  • Gutierrez, Daniela
  • Valle, Javier
  • Gómez-Casuso, Carmen E.S.
  • Sidelkivska, Valeriya
  • Alvarez, Alejandra
  • Perálvarez Marín, Alex
  • Suades, Albert
  • Fernàndez Busquets, Xavier
  • Andreu Martínez, David
  • Vicente García, Rubén, 1978-
  • Oliva Miguel, Baldomero
  • Muñoz López, Francisco José, 1964-
Alzheimer's disease (AD) is a neurodegenerative process characterized by the accumulation of extracellular deposits of amyloid β-peptide (Aβ), which induces neuronal death. Monomeric Aβ is not toxic but tends to aggregate into β-sheets that are neurotoxic. Therefore to prevent or delay AD onset and progression one of the main therapeutic approaches would be to impair Aβ assembly into oligomers and fibrils and to promote disaggregation of the preformed aggregate. Albumin is the most abundant protein in the cerebrospinal fluid and it was reported to bind Aβ impeding its aggregation. In a previous work we identified a 35-residue sequence of clusterin, a well-known protein that binds Aβ, that is highly similar to the C-terminus (CTerm) of albumin. In this work, the docking experiments show that the average binding free energy of the CTerm-Aβ1-42 simulations was significantly lower than that of the clusterin-Aβ1-42 binding, highlighting the possibility that the CTerm retains albumin's binding properties. To validate this observation, we performed in vitro structural analysis of soluble and aggregated 1 μM Aβ1-42 incubated with 5 μM CTerm, equimolar to the albumin concentration in the CSF. Reversed-phase chromatography and electron microscopy analysis demonstrated a reduction of Aβ1-42 aggregates when the CTerm was present. Furthermore, we treated a human neuroblastoma cell line with soluble and aggregated Aβ1-42 incubated with CTerm obtaining a significant protection against Aβ-induced neurotoxicity. These in silico and in vitro data suggest that the albumin CTerm is able to impair Aβ aggregation and to promote disassemble of Aβ aggregates protecting neurons., This work was supported by the Spanish Ministry of Economy and Business through grant Plan Estatal SAF2017-83372-R & SAF2014-52228-R (FEDER funds/UE) to FJM and RV; BIO2017-85329-R to BO; AGL2014-52395-C2 and AGL2017- 84097-C2-2-R to D.A.; MDM-2014-0370 through the “María de Maeztu” Programme for Units of Excellence in R&D to “Departament de Ciències Experimentals i de la Salut”; the Chilean Government through Fondecyt 11611065 and AFB170005 to AA, and REDES 180084 to AA and FJM; ISGlobal and IBEC are members of the CERCA Programme, Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Sensing low intracellular potassium by NLRP3 results in a stable open structure that promotes inflammasome activation

  • Tapia-Abellán, Ana
  • Angosto-Bazarra, Diego
  • Alarcón-Vila, Cristina
  • Baños, María C.
  • Hafner-Bratkovič, Iva
  • Oliva Miguel, Baldomero
  • Pelegrín, Pablo
  • Pelegrín, Pablo
The NLRP3 inflammasome is activated by a wide range of stimuli and drives diverse inflammatory diseases. The decrease of intracellular K+ concentration is a minimal upstream signal to most of the NLRP3 activation models. Here, we found that cellular K+ efflux induces a stable structural change in the inactive NLRP3, promoting an open conformation as a step preceding activation. This conformational change is facilitated by the specific NLRP3 FISNA domain and a unique flexible linker sequence between the PYD and FISNA domains. This linker also facilitates the ensemble of NLRP3PYD into a seed structure for ASC oligomerization. The introduction of the NLRP3 PYD-linker-FISNA sequence into NLRP6 resulted in a chimeric receptor able to be activated by K+ efflux–specific NLRP3 activators and promoted an in vivo inflammatory response to uric acid crystals. Our results establish that the amino-terminal sequence between PYD and NACHT domain of NLRP3 is key for inflammasome activation., I.H.-B. would like to acknowledge the funding by the Slovenian Research Agency (project grant J3-1746 and core funding P4-0176), and B.O. would like to acknowledge the funding by the Ministerio de Economía, Industria y Competitividad and ERDF (BIO2017-85329-R). This work was supported by grants to A.T.-A. from the internal support program of the Medical Faculty, University of Tübingen, Fortüne-Antrag Nr. 2615-0-0 and to P.P. from FEDER/Ministerio de Ciencia, Innovación y Universidades—Agencia Estatal de Investigación (grant SAF2017-88276-R), Fundación Séneca (grants 20859/PI/18, 21081/PDC/19, and 0003/COVI/20), and the European Research Council (ERC-2013-CoG grant 614578 and ERC-2019-PoC grant 899636).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

An ensemble learning approach for modeling the systems biology of drug-induced injury

  • Aguirre Plans, Joaquim, 1993-
  • Piñero González, Janet, 1977-
  • Souza, Terezinha
  • Callegaro, Giulia
  • Kunnen, Steven J.
  • Sanz, Ferran
  • Fernández Fuentes, Narcís
  • Furlong, Laura I., 1971-
  • Guney, Emre
  • Oliva Miguel, Baldomero
Background: Drug-induced liver injury (DILI) is an adverse reaction caused by the intake of drugs of common use that produces liver damage. The impact of DILI is estimated to affect around 20 in 100,000 inhabitants worldwide each year. Despite being one of the main causes of liver failure, the pathophysiology and mechanisms of DILI are poorly understood. In the present study, we developed an ensemble learning approach based on different features (CMap gene expression, chemical structures, drug targets) to predict drugs that might cause DILI and gain a better understanding of the mechanisms linked to the adverse reaction. Results: We searched for gene signatures in CMap gene expression data by using two approaches: phenotype-gene associations data from DisGeNET, and a non-parametric test comparing gene expression of DILI-Concern and No-DILI-Concern drugs (as per DILIrank definitions). The average accuracy of the classifiers in both approaches was 69%. We used chemical structures as features, obtaining an accuracy of 65%. The combination of both types of features produced an accuracy around 63%, but improved the independent hold-out test up to 67%. The use of drug-target associations as feature obtained the best accuracy (70%) in the independent hold-out test. Conclusions: When using CMap gene expression data, searching for a specific gene signature among the landmark genes improves the quality of the classifiers, but it is still limited by the intrinsic noise of the dataset. When using chemical structures as a feature, the structural diversity of the known DILI-causing drugs hampers the prediction, which is a similar problem as for the use of gene expression information. The combination of both features did not improve the quality of the classifiers but increased the robustness as shown on independent hold-out tests. The use of drug-target associations as feature improved the prediction, specially the specificity, and the results were comparable to previous research studies., The authors received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreements TransQST and eTRANSAFE (refs: 116030, 777365). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA companies in kind contribution. The authors also received support from Spanish Ministry of Economy (MINECO, refs: BIO2017–85329-R (FEDER, EU), RYC-2015-17519) as well as EU H2020 Programme 2014–2020 under grant agreement No. 676559 (Elixir-Excelerate) and from Agència de Gestió D’ajuts Universitaris i de Recerca Generalitat de Catalunya (AGAUR, ref.: 2017SGR01020). L.I.F. received support from ISCIII-FEDER (ref: CPII16/00026). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I + D + i 2013–2016, funded by ISCIII and FEDER. The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the MINECO (ref: MDM-2014-0370). J.A.P. received support from the CAMDA Travel Fellowship.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

On the use of direct-coupling analysis with a reduced alphabet of amino acids combined with super-secondary structure motifs for protein fold prediction

  • Anton, Bernat
  • Besalú, Mireia
  • Fornés Crespo, Oriol, 1983-
  • Bonet Martínez, Jaume, 1982-
  • Molina, Alexis
  • Molina Fernández, Rubén
  • Cuevas, Gemma de las
  • Fernández Fuentes, Narcís
  • Oliva Miguel, Baldomero
Direct-coupling analysis (DCA) for studying the coevolution of residues in proteins has been widely used to predict the three-dimensional structure of a protein from its sequence. We present RADI/raDIMod, a variation of the original DCA algorithm that groups chemically equivalent residues combined with super-secondary structure motifs to model protein structures. Interestingly, the simplification produced by grouping amino acids into only two groups (polar and non-polar) is still representative of the physicochemical nature that characterizes the protein structure and it is in line with the role of hydrophobic forces in protein-folding funneling. As a result of a compressed alphabet, the number of sequences required for the multiple sequence alignment is reduced. The number of long-range contacts predicted is limited; therefore, our approach requires the use of neighboring sequence-positions. We use the prediction of secondary structure and motifs of super-secondary structures to predict local contacts. We use RADI and raDIMod, a fragment-based protein structure modelling, achieving near native conformations when the number of super-secondary motifs covers >30-50% of the sequence. Interestingly, although different contacts are predicted with different alphabets, they produce similar structures., Spanish Ministry of Economy MINECO [BIO2014-57518-R, BIO2017-83591-R (FEDER, UE), BIO2017-85329-R (FEDER, UE)]; Generalitat de Catalunya [SGR17-1020].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

SPServer: split-statistical potentials for the analysis of protein structures and protein-protein interactions

  • Aguirre Plans, Joaquim, 1993-
  • Meseguer, Alberto
  • Molina Fernández, Rubén
  • Marín López, Manuel Alejandro, 1987-
  • Jumde, Gaurav
  • Casanova, Kevin
  • Bonet Martínez, Jaume, 1982-
  • Fornés Crespo, Oriol, 1983-
  • Fernández Fuentes, Narcís
  • Oliva Miguel, Baldomero
Background: Statistical potentials, also named knowledge-based potentials, are scoring functions derived from empirical data that can be used to evaluate the quality of protein folds and protein-protein interaction (PPI) structures. In previous works we decomposed the statistical potentials in different terms, named Split-Statistical Potentials, accounting for the type of amino acid pairs, their hydrophobicity, solvent accessibility and type of secondary structure. These potentials have been successfully used to identify near-native structures in protein structure prediction, rank protein docking poses, and predict PPI binding affinities. Results: Here, we present the SPServer, a web server that applies the Split-Statistical Potentials to analyze protein folds and protein interfaces. SPServer provides global scores as well as residue/residue-pair profiles presented as score plots and maps. This level of detail allows users to: (1) identify potentially problematic regions on protein structures; (2) identify disrupting amino acid pairs in protein interfaces; and (3) compare and analyze the quality of tertiary and quaternary structural models. Conclusions: While there are many web servers that provide scoring functions to assess the quality of either protein folds or PPI structures, SPServer integrates both aspects in a unique easy-to-use web server. Moreover, the server permits to locally assess the quality of the structures and interfaces at a residue level and provides tools to compare the local assessment between structures. SERVER ADDRESS: https://sbi.upf.edu/spserver/., This work was supported by the Spanish Ministry of Science and Innovation (MICINN) [BIO2017-85329-R (co-funded by ERDF,UE)]. BO also acknowledges support from MICINN [ref: MDM-2014-0370]. NFF acknowledges support from [BIO2017-83591-R (co-funded by ERDF, UE)] and [RYC-2015-17519]. We also akcnowledge support from the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and Grants PT13/0001/0023 of the PEI +D+i 2013–2016, funded by ISCIII and co-funded by ERDF of EU. BO and NFF acknowledge Agència de Gestió d’Ajuts Universitaris I de Recerca de la Generalitat de Catalunya, grant SGR17-1020, and the Council for the Catalan Republic contribution to cover the expenses of publication.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Human Albumin Impairs Amyloid β-peptide Fibrillation Through its C-terminus, From docking Modeling to Protection Against Neurotoxicity in Alzheimer's disease

  • Picón-Pagès, Pol
  • Bonet, Jaume
  • García-García, Javier
  • Garcia-Buendia, Joan
  • Gutiérrez, Daniela
  • Valle García, Javier|||0000-0002-6787-8286
  • Gómez-Casuso, Carmen E. S.
  • Sidelkivska, Valeriya
  • Alvarez, Alejandra
  • Peralvarez-Marin, Alex|||0000-0002-3457-0875
  • Suades, Albert
  • Fernández Busquets, Xavier|||0000-0002-4622-9631
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Vicente, Rubén|||0000-0003-0401-4808
  • Oliva Miguel, Baldomero|||0000-0003-0702-0250
  • Muñoz, Francisco J.
Alzheimer's disease (AD) is a neurodegenerative process characterized by the accumulation of extracellular deposits of amyloid β-peptide (Aβ), which induces neuronal death. Monomeric Aβ is not toxic but tends to aggregate into β-sheets that are neurotoxic. Therefore to prevent or delay AD onset and progression one of the main therapeutic approaches would be to impair Aβ assembly into oligomers and fibrils and to promote disaggregation of the preformed aggregate. Albumin is the most abundant protein in the cerebrospinal fluid and it was reported to bind Aβ impeding its aggregation. In a previous work we identified a 35-residue sequence of clusterin, a well-known protein that binds Aβ, that is highly similar to the C-terminus (CTerm) of albumin. In this work, the docking experiments show that the average binding free energy of the CTerm-Aβ simulations was significantly lower than that of the clusterin-Aβ binding, highlighting the possibility that the CTerm retains albumin's binding properties. To validate this observation, we performed in vitro structural analysis of soluble and aggregated 1 μM Aβ incubated with 5 μM CTerm, equimolar to the albumin concentration in the CSF. Reversed-phase chromatography and electron microscopy analysis demonstrated a reduction of Aβ aggregates when the CTerm was present. Furthermore, we treated a human neuroblastoma cell line with soluble and aggregated Aβ incubated with CTerm obtaining a significant protection against Aβ-induced neurotoxicity. These in silico and in vitro data suggest that the albumin CTerm is able to impair Aβ aggregation and to promote disassemble of Aβ aggregates protecting neurons.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan

  • Jorba, Guillem|||0000-0001-5209-5353
  • Aguirre-Plans, Joaquim|||0000-0002-1971-1350
  • Junet, Valentin|||0000-0002-6138-0612
  • Segú-Vergés, Cristina|||0000-0002-8215-872X
  • Ruiz, José Luis
  • Pujol, Albert
  • Fernández-Fuentes, Narcís
  • Mas, José Manuel
  • Oliva Miguel, Baldomero|||0000-0003-0702-0250
Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of different responses depending on the patient. Exploring this collection of mechanisms is one of the clues for a future personalized medicine. The Therapeutic Performance Mapping System (TPMS) is a Systems Biology approach that generates multiple models of the mechanism of action of a drug. Each molecular mechanism generated could be associated to particular individuals, here defined as prototype-patients, hence the generation of models using TPMS technology may be used for detecting adverse effects to specific patients. TPMS operates by (1) modelling the responses in humans with an accurate description of a protein network and (2) applying a Multilayer Perceptron-like and sampling strategy to find all plausible solutions. In the present study, TPMS is applied to explore the diversity of mechanisms of action of the drug combination sacubitril/valsartan. We use TPMS to generate a wide range of models explaining the relationship between sacubitril/valsartan and heart failure (the indication), as well as evaluating their association with macular degeneration (a potential adverse effect). Among the models generated, we identify a set of mechanisms of action associated to a better response in terms of heart failure treatment, which could also be associated to macular degeneration development. Finally, a set of 30 potential biomarkers are proposed to identify mechanisms (or prototype-patients) more prone of suffering macular degeneration when presenting good heart failure response. All prototype-patients models generated are completely theoretical and therefore they do not necessarily involve clinical effects in real patients.